Galapagos and abbvie expand their cystic fibrosis collaboration.
Patient trials expected to start in 2017.
Milestones increased from $350 to $600 million.
Companies have expanded their agreement in cystic fibrosis (cf) to reflect successful expansion of their cf portfolio.
Retains commercial rights to china and south korea, and has an option to co-promote in belgium, netherlands, and luxembourg.
Galapagos and abbvie aim to develop a triple cftr combination therapy to address 90% of patients with cf.
Source : reuters.com